DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pontocerebellar hypoplasia type 6 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePontocerebellar hypoplasia type 6 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pontocerebellar hypoplasia type 6 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Pontocerebellar hypoplasia type 6 is not mentioned in any of the provided abstracts. The abstracts discuss pontocerebellar hypoplasia types 1, 2, 4, 5, and 9, as well as an unclassified case with mutations in TSEN54 and EXOSC3. No abstract mentions a type 6 or any drug treatment for any subtype.
The 2011 review states that classification based on clinical, imaging, and neuropathological findings does not differentiate between subtypes with different genetic causes, and that not all cases of clinically defined PCH type 4 result from mutations in TSEN54. A 2019 case report describes a child with a heterozygote mutation in exon 8 of TSEN54 and in exon 1 of EXOSC3, presenting with seizures, feeding and swallowing disorders, strabismus, kyphoscoliosis, poor balance and coordination, mental retardation, severe speech impairment, hypotonia, and distinctive facial features. MRI showed microgyria, pontocerebellar hypoplasia, corpus callosum hypoplasia, and TH4 rachischisis. Uncontrolled seizures made the child’s condition unstable and he needed palliative care.
A 2014 report describes a two-year-old girl with PCH type 1 who had a relatively milder clinical phenotype with cerebellar atrophy but absent pontine involvement. A 2007 case of PCH type 1 in a four-year-old female found complex IV values of the mitochondrial respiratory chain at the lower limits of normal in muscle and skin fibroblasts. A 1997 report of two cases of PCH type 2 from Portuguese families describes neurological involvement from birth, progressive microcephaly, chorea, dystonia, myoclonic jerks, and progressive cerebral cortical atrophy; one child had consanguineous parents. The 2015 abstract notes that treatment for PCH is symptomatic and affected individuals often die during the neonatal period or infancy.
What is still missing for pontocerebellar hypoplasia type 6 specifically is any published clinical data, genetic characterisation, or natural history studies. For PCH generally, there are no disease-modifying therapies, no clinical trials, and no validated biomarkers to stratify patients by subtype or genetic cause.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Child Neurology · 2011 · 28 citations
Pontocerebellar Hypoplasia: Review of Classification and Genetics, and Exclusion of Several Genes Known to Be Important for Cerebellar Development
AbstractThe pontocerebellar hypoplasias are a heterogeneous group of rare and devastating conditions characterized by multiple structural abnormalities of the ventral pons, inferior olive, and cerebellum. Here, we briefly review these conditions and discuss genes recently discovered to be involved in pontocerebellar hypoplasia pathogenesis. We then present data that exclude several genes important for cerebellar development as causes of pontocerebellar hypoplasia-4 and pontocerebellar hypoplasia-5, and we demonstrate that not all cases of clinically defined pontocerebellar hypoplasia-4 result from mutations in TSEN54. We conclude that classification based on clinical, imaging, and neuropathological findings does not differentiate between pontocerebellar hypoplasia subtypes with different genetic causes.
Developmental Medicine & Child Neurology · 1997 · 10 citations · open access
Pontocerebellar hypoplasia with microcephaly and dyskinesia: report of two cases
AbstractWe present two clinically diagnosed cases of pontocerebellar hypoplasia with microcephaly and dyskinesia (pontocerebellar hypoplasia type 2) from two different Portuguese families. Both children presented neurological involvement from birth, progressive microcephaly, exuberant chorea and dystonia, myoclonic jerks, pontocerebellar hypoplasia, and progressive cerebral cortical atrophy. One child had consanguineous parents.
Hipoplasia pontocerebelosa tipo 1: aportación de un caso
AbstractINTRODUCTION: Pontocerebellar hypoplasias constitute a group of hereditary neurodegenerative disorders of uncertain aetiopathogenesis. They have been reported as being associated with deficiencies of complexes in the mitochondrial respiratory chain (MRC) and with congenital disorders of glycosylation. On the basis of clinical and neuropathological criteria, two phenotypes can be distinguished in this condition. Pontocerebellar hypoplasia type 1 is characterised by hypoplasia of the pons and the cerebellum associated with the degeneration of the motor neurons in the anterior horn of the spinal cord. CASE REPORT: A 4-year-old female with symptoms of severe psychomotor retardation associated with microcephaly, important generalised hypotonia, muscle hypotrophy, contractions in the four limbs, absence of stretch reflex and epilepsy with onset in the neonatal period. Magnetic resonance imaging of the brain revealed pontocerebellar hypoplasia. An electroneuromyography showed a trace that was compatible with axonal neuropathy and a biopsy of the deltoid muscle revealed the existence of neurogenic muscular atrophy. In the MRC study conducted in muscle homogenate and in skin fibroblasts, complex IV values were found to be at the lower limits of what could be considered to be normal levels. Results of the genetic study for spinal muscular atrophy were negative. CONCLUSIONS: The case reported here could be included as a case of pontocerebellar hypoplasia type 1. MRC studies can be of interest in cases of pontocerebellar hypoplasia in order to explain the role it plays in this disorder.
Journal of Pediatric Neurosciences · 2014 · 2 citations
Pontocerebellar hypoplasia type 1 with a milder phenotype in a two-year-old girl
AbstractThe rare association of pontocerebellar hypoplasia with anterior horn cell involvement has been classified as pontocerebellar hypoplasia type 1. Its classic phenotype is usually severe. However, the pontocerebellar hypoplasia type 1 may have wider variability in clinical and radiological features. There may be a genetic heterogeneity as well. We described here a young girl with relatively milder clinical phenotype with cerebellar atrophy with absent pontine involvement, further adding to the clinical phenotype.
P95 The undeclared new type of pontocerebellar hypoplasia
Abstract<h3>Background</h3> Pontocerebellar hypoplasia (PCH) refers to a group of severe neurodegenerative disorders affecting growth and function of the brainstem and cerebellum, resulting in serious neurological consequences or psychomotor delay. Different types are classified according to the clinical picture and the spectrum of pathologic changes. <h3>Method</h3> Clinical, genetic, molecular, encephalographic, radiological, pathological and survival data were gathered. <h3>Results</h3> The patient report presents the medical history of a pontocerebellar hypoplasia (PCH) child, which unrepresented in previous case histories. Our patient has a heterozygote mutation in 8 exon gene TSEN54 and in 1 exon in gene EXOSC3. It is important to note that such a mutation in TSEN54, however, in different exons is presented in PCH type 2A, PCH type 4 and PCH type 5 and a mutation in gene EXOSC3 is demonstrated in PCH1B. We compared all known PCH types (19 PCH types) and tried to find correlations between this child’s features and those associated with the other one. This case tries to resolve the diagnostic issues related to the combination of features of these different types simultaneously in one child. Clinical features include seizures, feeding and swallowing disorders, strabismus, kyphoscoliosis, poor balance and coordination, mental retardation, severe speech impairment, hypotonia. Our patient had some phenotype peculiarities, such as: brachycephalia, protruding brow arcs, preauricular excrescence, medial eyebrow flare, hypoplasia of the lower face, large nose, eyelids ptosis. The morphological changes of this case were microgyria, pontocerebellar hypoplasia, and corpus colosum hypoplasia. Moreover, an MRI confirmed TH4 rachischisis, and an ultrasound revealed thymomegaly and septal defects. An EEG demonstrated slow flashes with high-amplitude. In the frontal leads we can see epileptic discharges and periods of disorganization of cortical rhythm. EMG results were normal. Blood test showed no abnormalities. Uncontrolled seizures made the child’s condition unstable and he needed palliative care. <h3>Conclusion</h3> Therefore, our investigation continues to determine whether the child has a pontocerebellar hypoplasia (PCH) with undeclared molecular karyotype or has a combination of PCH type 2A, PCH type 4 and PCH type 5.
AbstractCase Study: Pontocerebellar hypoplasia (PCH) comprises a group of autosomal recessive neurodegenerative disorders with mostly prenatal onset. Clinical hallmarks are severe global developmental delay as well as specific neurologic symptoms depending on the subtype of PCH. Treatment is symptomatic and affected individuals often die during the neonatal period or infancy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
